Aisha Vadhariya

Aisha Vadhariya

Auto-generated profile, based on publicly available information

Aisha Vadhariya

Eli Lilly and Company, Indianapolis, Indiana, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2023 in Lupus Science & Medicine
Verified
Journal Article
Open access
PDF file
HBHermine I Brunner
Hermine I Brunner
AVAisha Vadhariya
Aisha Vadhariya
CDChristina Dickson
Christina Dickson
WCWallace Crandall
Wallace Crandall
CCCasey Kar-Chan Choong
Casey Kar-Chan Choong
ARAthimalaipet V Ramanan
Athimalaipet V Ramanan
Objective: To assess real-world treatment regimens and patterns in childhood-onset SLE (cSLE) and adult-onset SLE (aSLE) cohorts, including similarities in treatments, duration of use and adherence.Methods: This retrospective study utilised data from Merative L.P. MarketScan Research Databases (USA). Index date was the date of first SLE diagnosis (2010–2019). Patients aged <18 years (cSLE) and ≥18 years (aSLE) at index date with confirmed SLE diagnosis and ≥12 months continuous enrolment during pre-index and post-index periods were included. The cohorts were stratified based on the presence (existing) or absence (new) of pre-index SLE. Primary outcomes (post-index period) included treatment regimens (all patients), and adherence (proportion of days covered (PDC)) and discontinuation of therapies initiated within 90 days of diagnosis (new patients). Univariate comparisons between cSLE and aSLE cohorts were performed using Wilcoxon rank-sum and χ2(or Fisher’s exact) tests.Results: cSLE cohort included 1275 patients (mean age=14.1 years) and aSLE cohort included 66 326 patients (mean age=49.7 years). Antimalarials and glucocorticoids were commonly used among new (cSLE=64.4%/62.0%; aSLE=51.8%/49.7%) and existing (cSLE=68.6%/58.9%; aSLE=63.8%/51.3%) patients in both cohorts. Median oral glucocorticoid dose (prednisone equivalent) was higher in cSLE vs aSLE (new=22.1 vs 14.0 mg/day; existing=14.4 vs 12.3 mg/day; p<0.05). Mycophenolate mofetil use was higher in patients with cSLE vs aSLE (new=26.2% vs 5.8%; existing=37.6% vs 11.0%; p<0.0001). Compared with aSLE, more patients used combination therapies in cSLE (p<0.0001). Median PDC was higher in cSLE vs aSLE for antimalarials (0.9 vs 0.8; p<0.0001) and oral glucocorticoids (0.6 vs 0.3; p<0.0001). Treatment discontinuation was lower in cSLE vs aSLE for antimalarials (25.0% vs 33.1%; p<0.0001) and oral glucocorticoids (56.6% vs 71.2%; p<0.0001).Conclusions: Management of cSLE and aSLE includes the same medication classes; differences include more intensive use of therapy in cSLE, warranting the need for approved safe medications for cSLE.

1 January 2021 in Journal of the American Pharmacists Association
Verified
Journal Article
Open access
AVAisha Vadhariya
Aisha Vadhariya
RPRutugandha Paranjpe
Rutugandha Paranjpe
EEEkere J. Essien
Ekere J. Essien
MJMichael L. Johnson
Michael L. Johnson
Marc L FlemingMarc L Fleming
Marc L Fleming
SASusan Abughosh
Susan Abughosh
Despite a known benefit in the reduction of cardiovascular risk, adherence to statins remains suboptimal. A qualitative analysis was conducted within an intervention that identified trajectories of statin adherence in patients and used motivational interviewing (MoI) to improve adherence. The objective of this qualitative study was to evaluate transcripts of an MoI telephonic intervention to identify potential, past, and current barriers to statin adherence and barriers specific to distinct adherence trajectories. The MoI intervention was customized by past 1-year adherence trajectories (rapid discontinuation, gradual decline, and gaps in adherence). Two authors independently extracted and documented barriers from phone transcripts. Themes were derived from literature a priori and by cataloging recurring themes from the transcripts. The transcripts of calls made to 157 patients were reviewed of which 25.2% did not communicate a specific adherence barrier despite falling into a low-adherence trajectory when examining refill data. The most commonly reported barriers to statin adherence included adverse effects (40.1%), forgetfulness (30.0%), and lack of skills or knowledge pertaining to statins (25%). More patients in the rapid discontinuation group perceived medication as unnecessary, whereas more patients in the gaps in adherence group reported a communication barrier with their health care provider. Several barriers among patients who fell into low-adherence trajectories were reported. Some patients did not report any barriers, which may have indicated denial. MoI phone calls were useful in providing knowledge, clarifying medication regimens, and reinforcing the need to take statins. This study identified patient-reported barriers to statin adherence elicited during an MoI telephonic intervention conducted by student pharmacists. There were differences in barriers reported by patients from each trajectory, which emphasize the need for additional tailored interventions to improve patient adherence.

17 February 2025 in Journal of Patient-Reported Outcomes
Verified
Journal Article
Open access
PDF file
JLJames D. Lewis
James D. Lewis
AVAisha Vadhariya
Aisha Vadhariya
SSSylvia Su
Sylvia Su
XZXian Zhou
Xian Zhou
FDFrederick Durand
Frederick Durand
SSStefan Schreiber
Stefan Schreiber
Background: The Stool Frequency (SF) and Abdominal Pain (AP) items from the Crohn’s Disease Activity Index are together referred to as the “Patient Reported Outcome” (PRO). The SF item measures the number of very soft/liquid stools and the AP item measures abdominal pain severity, which are common Crohn’s disease (CD) symptoms that patients consider important to treat. This study evaluated the psychometric properties of both PRO items separately and estimated thresholds for clinical remission in moderately to severely active CD. Methods: The measurement properties of the PRO items were analyzed using pooled data from VIVID-1 (NCT03926130), a Phase 3, randomized, placebo- and active-controlled study in adults with moderately to severely active CD. Analyses used weekly average scores of the SF and AP items at Weeks 0 (Baseline), 4, 12, and 52. Remission thresholds were estimated using the Patient Global Rating of Severity (PGRS) and Patient Global Impression of Change (PGIC) as primary anchors as well as qualitative evidence from exit interviews. Results: Data from 1065 participants (mean age: 36.2 years [standard deviation: 13 years]) were analyzed. During the trial, scores improved for both PRO items. Both items demonstrated moderate-to-good test-retest reliability for participants defined as stable based on PGRS and PGIC. Most correlations of related assessments were moderate (0.30≤|ρ| <0.70) with SF and moderate-to-large (0.30≤|ρ| ≤0.90) with AP. By contrast, as anticipated, both items had weak correlations (|ρ| <0.30) with endoscopic and laboratory assessments. The PRO items could discriminate between groups of participants known to differ based on other assessments. The PRO items were able to detect change, as score changes in both items between Baseline and Weeks 12 and 52 differed significantly between most PGRS and PGIC categories. Anchor-based analyses combined with responses from the exit interviews suggested that an SF score of ≤ 3 and an AP score of ≤ 1 could together represent clinical remission. Conclusion: These results support the reliability, construct-validity, and responsiveness of both PRO items in moderately to severely active CD and confirm previously suggested scores for both items that could represent clinical remission. Trial registration: Clinicaltrials.gov, NCT03926130. Registered 23 April 2019, https://clinicaltrials.gov/study/NCT03926130.

18 December 2024 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
MDMarla Dubinsky
Marla Dubinsky
AVAisha Vadhariya
Aisha Vadhariya
SSSylvia Su
Sylvia Su
XZXian Zhou
Xian Zhou
FDFrederick Durand
Frederick Durand
STSimon Travis
Simon Travis
Introduction Bowel urgency has recently been recognized as a Crohn’s disease (CD) symptom that substantially impacts patients’ quality of life. The Urgency NRS is a single-item patient-reported outcome measure assessing bowel urgency severity in the past 24 h (0–10 scale). We aimed to evaluate the psychometric properties of the Urgency Numeric Rating Scale (NRS) in adults with moderately to severely active CD and to estimate thresholds for meaningful improvement and bowel urgency remission. Methods Psychometric analyses used pooled data from the Phase 3 VIVID-1 study of mirikizumab, where participants with CD completed the Urgency NRS and other assessments. The Patient Global Rating of Severity (PGRS) and Patient Global Impression of Change (PGIC) were used as primary anchors to estimate Urgency NRS thresholds representing meaningful improvement and remission. Results The Urgency NRS showed good test–retest reliability in participants who were stable based on PGRS and PGIC. It was moderately correlated with similar assessments and weakly correlated with endoscopic/laboratory assessments. It differentiated between participant subgroups varying in disease severity and quality of life based on PGRS and other assessments. It was sensitive to change, as Urgency NRS improvements during the trial differed between most PGRS change and PGIC categories. A 3–5-point reduction on the Urgency NRS represented meaningful improvement and a score of ≤ 2 represented remission. Conclusion The Urgency NRS demonstrated strong psychometric properties in the VIVID-1 population of moderately to severely active CD. Analyses also suggested meaningful improvement and remission thresholds. Trial Registration Clinicaltrials.gov, NCT03926130. Registered 23 April 2019, https://clinicaltrials.gov/study/NCT03926130.

20 August 2024 in Rheumatology and Therapy
Verified
Journal Article
Open access
ADAbhijeet Danve
Abhijeet Danve
AVAisha Vadhariya
Aisha Vadhariya
JLJeffrey Lisse
Jeffrey Lisse
ACArjun Cholayil
Arjun Cholayil
NBNeha Bansal
Neha Bansal
CBCatherine Bakewell
Catherine Bakewell
Real-world data on ixekizumab utilization in axial spondyloarthritis (axSpA) are limited. We evaluated ixekizumab treatment patterns and health care resource utilization (HCRU) in patients with axSpA using United States Merative L.P. MarketScan® Claims Databases. This retrospective cohort study included adults with axSpA who initiated ixekizumab during the index period (September 2019-December 2021). Index date was the date of the first ixekizumab claim. All patients had continuous medical and pharmacy enrollment during the 12-month pre-index and follow-up periods. Descriptive statistics were used to assess patient demographics (index date); clinical characteristics (pre-index period); treatment patterns (12-month follow-up period); and HCRU (pre-index and 12-month follow-up periods). The study included 177 patients (mean age 45.8 years; females 54.8%) with axSpA who initiated ixekizumab. Overall, 79.1% of patients reported prior biologic use; of these, 70.7% received tumor necrosis factor-alpha inhibitors (TNFi) and 49% received secukinumab. The mean (standard deviation [SD]) Charlson Comorbidity Index score was 1.1 (1.3) and ~ 27% of patients reported ≥2 comorbidities. The median (inter-quartile range [IQR]) number of ixekizumab prescription refills was 7 (4-11). The mean (SD) Proportion of Days Covered (PDC) for ixekizumab was 0.6 (0.3) and adherence (PDC ≥80%) was 34.5% (N = 61). Overall, 26.6% (N = 47) of patients switched to a non-index medication and 54.2% (N = 96) of patients discontinued ixekizumab. Among the patients who discontinued ixekizumab (N = 96), 19.8% (N = 19) restarted ixekizumab and 49.0% (N = 47) switched to a non-index medication. The median (IQR) ixekizumab persistence was 268 (120-366) days. Mean axSpA-related outpatient, inpatient, and emergency room visits were similar between the pre-index and follow-up periods. Treatment patterns were largely similar between biologic-experienced patients (N = 140; 79.1%) and the overall population. Despite high comorbidity burden and majority of the patients being biologic-experienced, patients initiating ixekizumab for axSpA showed favorable persistence profiles during the 12-month follow-up period.

13 March 2025 in American Journal of Gastroenterology
Verified
Journal Article
Open access
SLScott D. Lee
Scott D. Lee
SVSeverine Vermeire
Severine Vermeire
RURyan Ungaro
Ryan Ungaro
AVAisha Vadhariya
Aisha Vadhariya
FDFrederick Durand
Frederick Durand
MLMillie Long
Millie Long
INTRODUCTION: Mirikizumab demonstrated significant efficacy compared with placebo in patients with Crohn's disease (CD) in the phase 3 VIVID-1 study. In this study, we report the impact of mirikizumab vs placebo on health-related quality of life (HRQoL) and work productivity in VIVID-1. METHODS: VIVID-1 patients randomized to receive mirikizumab (N = 579), or placebo (N = 199) were included. The effect of mirikizumab on HRQoL was assessed at weeks 12 and 52 using the Inflammatory Bowel Disease Questionnaire (IBDQ), Short Form-36 Health Survey (SF-36), EQ-5D-5L visual analog scale, and Work Productivity and Activity Impairment: CD measures. The Cochran-Mantel-Haenszel test with nonresponder imputation (binary end points) and analysis of covariance with modified baseline observation carried forward (continuous end points) were used for treatment comparisons. RESULTS: Greater improvements in the mean change from baseline to weeks 12 and 52 were observed with mirikizumab vs placebo in IBDQ total and domain scores, SF-36 summary and domain scores, and EQ-5D-5L visual analog scale scores (all P < 0.001). Significant improvements with mirikizumab vs placebo were observed in Work Productivity and Activity Impairment:CD scores at week 12: absenteeism (P = 0.001), presenteeism (P = 0.005), activity impairment (P < 0.001), and overall work impairment (P = 0.002); these improvements were maintained at week 52 (all P < 0.001, except absenteeism). At weeks 12 and 52, a greater proportion of mirikizumab-treated patients vs placebo achieved IBDQ response, IBDQ remission, and clinically important improvement in physical and mental component summaries of SF-36 (all P < 0.001). DISCUSSION: Patients with moderately to severely active CD treated with mirikizumab reported clinically meaningful improvements in HRQoL and work productivity vs placebo at week 12, which were maintained at week 52.